المؤلفون: Y. K. Park, J. G. Shin

المصدر: Journal of Mechanical Science and Technology. 31:1789-1796

مصطلحات موضوعية: musculoskeletal diseases, Materials science, business.industry, Mechanical Engineering, technology, industry, and agriculture, Fatigue testing, 02 engineering and technology, Welding, Structural engineering, respiratory system, 01 natural sciences, Fatigue limit, Finite element method, law.invention, 010101 applied mathematics, 020303 mechanical engineering & transports, Discontinuity (geotechnical engineering), 0203 mechanical engineering, Mechanics of Materials, law, Research studies, Stress singularity, 0101 mathematics, business, Stress concentration

الوصف: Fatigue failure is a grave technical issue in welded structures; it is caused by the stress concentration at the discontinuity of the weld toe or root. Therefore, many research studies have been performed to establish appropriate S–N curves for welded joints via fatigue tests and Finite element analysis (FEA). In almost all fatigue tests, it has been found that the loading point is far from the points of concern where fatigue life is investigated, and the fatigue life of the welded joint is not affected by the stress singularity at the loading points. However, when the loading point is close to the welded joint, the peak stress at the welded joint is affected by both geometry discontinuity at the welded joint and uneven stress distribution at the loading point. This paper presents the validity of S–N curves for welded structures with a concentrated load close to the welded joint. The stress behaviors of structures with a concentrated load are defined via stress measurements and FEA. Fatigue evaluations are performed via fatigue tests and corresponding FEA.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::80d60a266e49ee553d6d4e5bd45e4943Test
https://doi.org/10.1007/s12206-017-0326-7Test

المؤلفون: Jinbae Kim, J. G. Shin, S. H. Kim

المصدر: Journal of Physics: Conference Series. 1284:012036

مصطلحات موضوعية: History, Computer science, Human–computer interaction, Critical design, Computer Science Applications, Education

الوصف: The advancements in artificial intelligence technology have made changes in how people interact with systems. Unique features and user requirements of Human-AI Interactions (HAII) need to be identified with respect to those of Human-Computer interactions (HCI). This study proposes a way to find critical parameters of interaction design for enhancing user’s satisfaction when people interact with intelligent systems through voice user interfaces. We summarised distinguished user requirements for intelligent products identified from previous researches. Then match them with design parameters in terms of performance indexes that will make differences in the user’s satisfaction. The interaction scenario was set as users ask simple questions with their own voices to the system and the system answer to the questions with synthesized voices after it got to the answer by AI function. The critical performance indexes derived are the number of trials to get the right answer for a question, response time to get to the next interaction, sentence structures of the answer, and pace of the answer. An experimental setup is ready to evaluate user’s satisfaction among different levels of the above performance indexes by Wizard of Oz design method applied on a voice user interface we implement. We are going to validate the effects of performance indexes in HAII on the user’s satisfaction, which will be measured in terms of verbal and non-verbal measures.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::a7c376b4841f9f55066f69d851155e7fTest
https://doi.org/10.1088/1742-6596/1284/1/012036Test

المؤلفون: M. Yi, S.A. Cho, Masud Parvez, S.J. Lee, J.-G. Shin, D.H. Kim, J.A. Jung

المصدر: Clinical Therapeutics. 39:e61

مصطلحات موضوعية: Pharmacology, Genetics, CYP4F11, Erythromycin metabolism, business.industry, Genetic variants, Medicine, Pharmacology (medical), Identification (biology), business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::087151688a5329de25e4b382f9f0b01aTest
https://doi.org/10.1016Test/j.clinthera.2017.05.188

المؤلفون: E. Kim, H. Jung, J.-G. Shin, Jon Suh, S. Choi

المصدر: Clinical Therapeutics. 39:e50

مصطلحات موضوعية: Pharmacology, Iodinated contrast media, business.industry, Immunology, Genotype, Medicine, Pharmacology (medical), Human leukocyte antigen, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ac4c01aaa4ed85326d5939ce0685c353Test
https://doi.org/10.1016Test/j.clinthera.2017.05.155

المؤلفون: H. W. Choi, J. G. Shin

المصدر: Applied Mathematics and Computation. 146:257-271

مصطلحات موضوعية: Computational Mathematics, Nonlinear system, Polynomial, Applied Mathematics, ComputingMethodologies_SYMBOLICANDALGEBRAICMANIPULATION, Pattern matching, Decomposition method (constraint satisfaction), Algebraic number, Trigonometry, Symbolic computation, Adomian decomposition method, Algorithm, Mathematics

الوصف: In this paper, a symbolic implementation code is developed of a technique proposed by Wazwaz [Appl. Math. Comput. 111 (2000) 53] for calculating Adomian polynomials for nonlinear operators. The algorithm proposed by him [Appl. Math. Comput. 111 (2000) 53] offers a promising approach for calculating Adomian polynomials for all forms of nonlinearity, but it is not easy to implement due to its huge size of algebraic calculations, complicated trigonometric terms, and unique summation rules. It is well known that the algebraic manipulation language such as Mathematica is useful to facilitate such a hard computational work. Pattern-matching capabilities peculiar feature of Mathematica are used in index regrouping which is a key role in constructing Adomian polynomials. The computer algebra software Mathematica is used to collect terms to their order and to simplify the terms. The symbolic implementation code author developed (appearing at appendix) has the flexibility that may easily cover any length of Adomian polynomial for many forms of nonlinear cases. A nonlinear evolution equation is investigated in order to justify the availability of symbolic implementation code.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::316bc557276323eb9d1ef2ca9812c741Test
https://doi.org/10.1016/s0096-3003Test(02)00541-6

المؤلفون: J H, Shon, N, Kim, S J, Park, M K, Oh, E Y, Kim, S H, Lee, Y H, Kim, J G, Shin

المصدر: Diabetes, obesitymetabolism. 16(10)

مصطلحات موضوعية: Male, Dipeptidyl-Peptidase IV Inhibitors, Pyrimidines, Metabolic Clearance Rate, Renal Dialysis, Area Under Curve, Creatinine, Humans, Female, Renal Insufficiency, Piperidones

الوصف: This study evaluated the effects of renal impairment (RI) and haemodialysis (HD) on the pharmacokinetics of gemigliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor. After a 100 mg administration to subjects with normal renal function (n = 23) or RI (n = 24), plasma, urine or dialysate samples were analysed. Control subjects were matched to patients based on age, gender and body mass index. Patients with mild, moderate, severe RI and end-stage renal disease (ESRD) showed 1.20, 2.04, 1.50 and 1.66-fold (1.10, 1.49, 1.22 and 1.21-fold) increase of mean area under the time-plasma concentration curve from 0 to infinity (AUCinf) [maximum plasma concentration (Cmax)] of gemigliptin, respectively. Pharmacokinetics of gemigliptin was comparable between HD and non-HD periods in ESRD patients. Less than 4% of the dose was removed by 4 h HD. RI appeared to have modest effect on the gemigliptin disposition. No dose adjustment in patients with RI is proposed on the basis of exposure-response relationship. Impact of HD on the removal of gemigliptin was negligible.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::6594fe48079f8572858ba73ab23b3234Test
https://pubmed.ncbi.nlm.nih.gov/24641348Test

المؤلفون: E.-J. Shim, H.-S. Kim, M. Oh, Y.-J. Lim, E.-Y. Kim, B.-S. Moon, Ji-Hong Shon, G.-S. Song, J.-G. Shin

المصدر: Drug research. 63(12)

مصطلحات موضوعية: Adult, Toluidines, Cmax, Hydroxybutyrates, Bioequivalence, Pharmacology, chemistry.chemical_compound, Young Adult, Pharmacokinetics, Drug Discovery, Teriflunomide, Nitriles, Republic of Korea, Medicine, Humans, Active metabolite, Leflunomide, Analysis of Variance, Cross-Over Studies, Dose-Response Relationship, Drug, business.industry, General Medicine, Isoxazoles, Middle Aged, Crossover study, chemistry, Therapeutic Equivalency, Antirheumatic Agents, Area Under Curve, Crotonates, business, medicine.drug, Blood sampling

الوصف: Leflunomide is a disease-modifying antirheumatic drug. The purpose of this study was to evaluate the bioequivalence of a test drug (CJ leflunomide) and a commercially available reference drug (Arava®) at 2 doses (10 and 20 mg) in healthy Korean volunteers. This was a single-dose (28 individuals enrolled at each dose group), randomized, open-label, 2-way crossover study. The 2 treatment periods were separated by a 56-day wash-out interval. Blood sampling was conducted until 672 h after drug administration. Plasma teriflunomide (active metabolite of leflunomide) concentrations were determined, and pharmacokinetic parameters were calculated. Bioequivalence was evaluated using an ANOVA model, based on the AUCt and the Cmax after administration of leflunomide tablets. Bioequivalence was defined as the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of AUCt and Cmax for the test and reference drugs being within the range of 0.80-1.25. The GMRs (90% CI) for AUCt and Cmax were 0.9506 (0.9091-0.9941) and 0.9861 (0.9360-1.0389), respectively, in the 10 mg study, and 0.9524 (0.9101-0.9968) and 0.9740 (0.9314-1.0186), respectively, in the 20 mg study. The 90% CIs of AUCt and Cmax at each dose were within the accepted range for bioequivalence. Based on the results, the test drug (CJ leflunomide) was bioequivalent to the commercially available reference drug (Arava®) at both doses.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40d07117168973db283a6dd0d453899fTest
https://pubmed.ncbi.nlm.nih.gov/23884659Test

المؤلفون: P Krippl, M-T M Lee, Alan H.B. Wu, E Haschke-Becher, Vera J. Suman, Yusuke Nakamura, R Ferraldeschi, Teri E. Klein, U Hamann, Werner Schroth, M Schmidt, Christine B. Ambrosone, Julia C. Stingl, Wendy Lorizio, Richard M. Weinshilboum, Gary Zirpoli, Michel Eichelbaum, JN Ingle, Michael A. Province, P Wegman, Li Gong, Anthony Howell, Matthias W. Beckmann, Virgil Craig Jordan, AM Thompson, Hitoshi Zembutsu, A-S Dieudonné, Russ B. Altman, Ayse Latif, Stefan Winter, S Wingren, J-Y Choi, T Mushiroda, J-G Shin, Matthias Schwab, Matthew M. Ames, Ryan Whaley, David A. Flockhart, Anne T. Nguyen, Lee B. Jordan, Patrick Neven, William G. Newman, U Langsenlehner, Elad Ziv, Colin A. Purdie, Matthew P. Goetz, Joan M. Hebert, Philip R. Quinlan, Peter A. Fasching, Hiltrud Brauch, W Renner, Diether Lambrechts, B-W Park, Kazuma Kiyotani

المصدر: Clinical pharmacology and therapeutics. 95(2)

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Genotype, Breast Neoplasms, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, Humans, Pharmacology (medical), skin and connective tissue diseases, Prospective cohort study, Survival analysis, Aged, Pharmacology, Gynecology, business.industry, Hazard ratio, Genetic Variation, Middle Aged, medicine.disease, Survival Analysis, Confidence interval, 3. Good health, Tamoxifen, Treatment Outcome, Cytochrome P-450 CYP2D6, Pharmacogenetics, 030220 oncology & carcinogenesis, Meta-analysis, Female, Menopause, business, medicine.drug

الوصف: The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9c5c363cdd61da0c6ca166b01e5660Test
https://pubmed.ncbi.nlm.nih.gov/25056391Test

المؤلفون: H W, Lee, M-s, Lim, J, Lee, M-Y, Jegal, D-W, Kim, W-K, Lee, I-J, Jang, J-G, Shin, Y-R, Yoon

المصدر: Journal of clinical pharmacy and therapeutics. 37(1)

مصطلحات موضوعية: Adult, Male, Polymorphism, Genetic, Genotype, Sequence Analysis, DNA, Young Adult, Sulfonylurea Compounds, Asian People, Area Under Curve, Republic of Korea, Humans, Hypoglycemic Agents, Female, Aryl Hydrocarbon Hydroxylases, Alleles, Cytochrome P-450 CYP2C9, Retrospective Studies

الوصف: Cytochrome P450 (CYP) 2C9 is a clinically important enzyme involved in the metabolism of many drugs commonly used in humans. Of several allelic variants known to affect the catalytic activity of the CYP2C9 enzyme, the frequencies of the CYP2C9*3 and CYP2C9*13 alleles in the Korean population have been reported as 1·1% and 0·6%, respectively. Our objective was to re-evaluate the frequencies of CYP2C9 allelic variants in the Korean population, including the CYP2C9*13 allele by pyrosequencing, and to investigate the pharmacokinetics of glimepiride in relation to CYP2C9 genotypes, including CYP2C9*3/*3.295 subjects were genotyped for CYP2C9*2 and CYP2C9*3 using the TaqMan procedure, and for CYP2C9*13 using pyrosequencing. These data were combined with our previously reported data to assess the CYP2C9 allele and genotype frequencies in 869 Korean subjects. Data from 24 of the 295 genotyped subjects (22 CYP2C9*1/*1 homozygotes, one CYP2C9*1/*3 heterozygote and one CYP2C9*3/*3 homozygote) who had participated in a bioequivalence study were analysed retrospectively to examine the effects of CYP2C9 genotype on glimepiride pharmacokinetics.The frequencies of the CYP2C9*1/*3, *3/*3, and *1/*13 genotypes in the study population (n = 295) were 0·081 (n = 24), 0·010 (n = 3) and 0·003 (n = 1), respectively. In the 869 subjects from the combined studies, allele frequencies for CYP2C9*3 and CYP2C9*13 were 0·025 (95% CI: 0·018, 0·033) and 0·002 (95% CI: 0·000, 0·010), respectively. Relative to CYP2C9*1 homozygotes, the one CYP2C9*3 homozygous subject was found to have a higher AUC(0-∞) value (490% of the reference value) and a lower oral clearance rate (18% of the reference).This study is the first examination of CYP2C9*3 homozygotes in the Korean population. Our data on the one subject with this genotype suggest that CYP2C9*3/*3 momozygotes have lower clearance of glimepiride and are exposed to higher levels of the drug than wild-type homozygotes. Although we identified a subject with the CYP2C9*13 allele using a new pyrosequencing assay, we were unfortunately unable to investigate its effects on glimepiride pharmacokinetics.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::ebd393e7e0e9c228c09712dd44df1ad2Test
https://pubmed.ncbi.nlm.nih.gov/21208246Test

المؤلفون: J K Lee, H J Kang, J G Shin

المصدر: Systems Engineering in Ship & Offshore Design 2010.

مصطلحات موضوعية: Process management, Computer science, Support system, Business model

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7c0357e56957c01d83fb4c5e35b9f467Test
https://doi.org/10.3940/rina.sod.2010.12Test